No reduction in cardiovascular risk with NSAIDs-including aspirin?
Cleland
John G F
JG
Department of Cardiology, University of Hull, HU16 5JQ, Kingston upon Hull, UK. j.g.cleland@medschool.hull.ac.uk
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use*; D015982:Bias; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D012107:Research Design / Q000592:standards; D012189:Retrospective Studies; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin